NCT06146114View on ClinicalTrials.gov

Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

December 1, 2024

Conditions
HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
Interventions
DIAGNOSTIC_TEST

Collect HER2 expression in prostate cancer patients

HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023

Trial Locations (1)

276600

RECRUITING

Qilu hospital, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER